Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
Primary Industries
- Drugs
- Therapeutic
- Disease
- Pharmaceuticals
- Technical Know How
- Medical
- Drug Discovery
- Molecular
- Nerve
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 146229
License Grant
The company entered into an agreement for the exclusive license worldwide to research, develop, and commercialize ATI-9242, a novel antipsychotic for the treatment of schizophrenia and other psychiatric disorders.
License Property
ATI-9242, a novel antipsychotic for the treatment of schizophrenia and other psychiatric disorders.
Field of Use
This agreement pertains to the drug industry.
IPSCIO Record ID: 28679
License Grant
The Israeli Licensee completed the Agreement for obtaining an exclusive global License to the Israeli Licensor's entire technology regarding mental health diseases.
Licensor hereby grant to XTL an exclusive, world-wide, perpetual, irrevocable, license to develop, have developed, manufacture, have manufactured, produce, have produced, use, provide, market, offer for sale, sell, have sold, export and import Licensed Products (the 'License').
License Property
The technology transferred to the Company according to the License is patent protected until 2027.
The SAM-101 is a drug (combination drug to treat mental disorders focusing on schizophrenia).
COMBINED THERAPIES OF ANTIPSYCHOTIC DRUGS AND TETRACYCLINES IN THE TREATMENT OF PSYCHIATRIC DISORDERS – The present invention relates to the use of combinations of an antipsychotic drug and a tetracycline in the treatment of psychiatric disorders, particularly schizophrenia. The invention describes the composition, methods of use, type of formulations, methods of administration, and a kit for the use of said combinations. The invention also provides methods for a combined therapy for treatment of psychiatric disorders, particularly schizophrenia, comprising an antipsychotic drug and a tetracycline. The invention also provides a method for delaying or preventing the onset of schizophrenia.
US Prov.
60/852646
19/Oct/2006
USA
12/446444
18/Oct/2007
Field of Use
The Licensee is engaged in the development of drugs, among others for the treatment of unmet medical needs as well as improvement of existing medical treatments and business ventures in the medical industry.
The Licensee will conduct clinical trials, develop, register, market, distribute and sell the drugs arising from the developed technology, regardless of a specific disease.
IPSCIO Record ID: 3004
License Grant
The Licensee from Israel has acquired the U.S. and Canadian rights to commercialize AZ-004, a novel formulation of loxapine administered via deep lung inhalation using the Israel Licensor's proprietary Staccato® device.
Field of Use
AZ-004 is initially targeted for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder. Staccato® loxapine combines Licensor's proprietary Staccato® single dose inhaler drug delivery system with the antipsychotic drug loxapine.
IPSCIO Record ID: 166962
License Grant
Licensor grants an exclusive license in the field under the patents and know-how to develop, have developed, make, have made, use, import, sell, offer for sale and have sold Compound and Product in the Territory.
Licensor grants a non-exclusive, worldwide license to make or use any analytical reference standards, intermediate or metabolite of Compound or Product not listed hereto which may be claimed.
License Property
Licensor is the owner of all right, title and interest in certain patents and patent applications and know-how relating to the chemical compound known as Iloperidone.
Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.
Field of Use
The field shall mean the treatment in humans of psychiatric disorders, psychotic disorders and analgesia.
IPSCIO Record ID: 212736
License Grant
Pursuant to which University has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of “Bryostatin Compounds and Methods of Preparing the Same,†or synthesized bryostatin, for use in the treatment of neurological diseases, cognitive dysfunction and psychiatric disorders, for the life of the licensed patents.
License Property
Bryostatins are a group of macrolide lactones isolated from the marine organism, Bugula neritina. Bryostatins are potent modulators of protein kinase C,
The technology relates to bryostatin, for use in the treatment of neurological diseases, cognitive dysfunction and psychiatric disorders.
Field of Use
This agreement pertains to the drug industry.
IPSCIO Record ID: 204326
License Grant
Licensor shall promote, market and sell Product under a registered Licensor trademark(s) approved by Licensee. Licensor shall grant Licensee or its designee(s) a trademark license.
Licensor shall license or otherwise make available under applicable law the benefit of such approvals or work to Licensee or an Affiliate or Third Party designated by Licensee who shall have the rights to develop, register, manufacture, market and sell Compound and Product in such country(ies) utilizing such approvals or work.
License Property
The licensed property means the chemical compound known as Iloperidone. Iloperidone is an atypical antipsychotic for the treatment of schizophrenia.
Field of Use
The field shall mean the treatment in humans of psychiatric disorders, psychotic disorders and analgesia.
IPSCIO Record ID: 303332
License Grant
With this agreement, the Licensee now holds a license to certain patents and know-how of Licensor. The licensed rights are exclusive.
License Property
The patents and know-how of Licensor are relating to lumateperone and other specified compounds. CAPLYTATM (lumateperone) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults (42mg/day). CAPLYTA refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults, and lumateperone refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia. Lumateperone is in Phase 3 clinical development as a novel treatment for bipolar depression.
Field of Use
This agreement provides the Company with a portfolio of compounds with potential to be effective treatments for schizophrenia and other therapies for CNS indications such as Tourette's syndrome, Bipolar Disorder, and Obsessive-Compulsive Disorder.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
